U.S. Markets closed

Baudax Bio, Inc. (BXRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.7804-0.0039 (-0.50%)
At close: 4:00PM EDT

Baudax Bio, Inc.

490 Lapp Road
Malvern, PA 19355
United States
484 395 2440

Full Time Employees57

Key Executives

NameTitlePayExercisedYear Born
Dr. Geraldine A. HenwoodPres, CEO & Director441.06kN/A1952
Mr. Richard S. Casten CPA, M.B.A.Chief Financial OfficerN/AN/A1974
Dr. Stewart McCallumChief Medical OfficerN/AN/A1966
Ms. Diane MyersSr. VP of Regulatory & QualityN/AN/A1964
Dr. Jyrki MattilaExec. VP of Bus. Devel.N/AN/A1955
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Corporate Governance

Baudax Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.